CSL entered a partnership with Alentis Therapeutics to co-develop and co-promote lixudebart, a potential…
Key takeaway
CSL pays $355m upfront plus up to $1.2bn in milestones to co-develop lixudebart with Alentis Therapeutics.
- Step 1 · The triggerCSL pays $355m upfront to Alentis for co-development rights to lixudebart
- Step 2 · Knock-onAlentis receives non-dilutive funding, accelerating its rare disease pipeline
- Step 3 · Knock-onCSL expands its rare kidney/liver disease portfolio, potentially increasing future revenue
- Step 4 · Reaches youUS biotech SMEs see increased partnering interest from large pharma seeking external innovation
The trigger is reported by the source below. The steps that follow are Branch²’s traced reasoning — how the shock could reach a business like yours, not a prediction.
Source: Google News US Business
See what today’s news does to your business. Atri by Branch² — Early-warning intelligence for your businessThis is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.